In SS, the situation is partially different: although ERK1/2 MAPK signaling pathway components have been proposed as targets of SS18-SSX, few reports describing their role and druggability in SS are available so far [181, 182]. This evidence concerns the gene MAPK3 and synovial sarcoma.